These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 18160809)
1. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer. Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408 [TBL] [Abstract][Full Text] [Related]
3. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401 [TBL] [Abstract][Full Text] [Related]
4. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961 [TBL] [Abstract][Full Text] [Related]
5. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971 [TBL] [Abstract][Full Text] [Related]
6. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246 [TBL] [Abstract][Full Text] [Related]
7. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer. Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564 [TBL] [Abstract][Full Text] [Related]
8. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Wang CS; Wu TL; Tsao KC; Sun CF Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233 [TBL] [Abstract][Full Text] [Related]
9. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Ishida H; Murata N; Hayashi Y; Tada M; Hashimoto D Surg Today; 2003; 33(12):885-92. PubMed ID: 14669077 [TBL] [Abstract][Full Text] [Related]
11. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030 [TBL] [Abstract][Full Text] [Related]
12. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Zeng ZS; Cohen AM; Zhang ZF; Stetler-Stevenson W; Guillem JG Clin Cancer Res; 1995 Aug; 1(8):899-906. PubMed ID: 9816060 [TBL] [Abstract][Full Text] [Related]
13. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Birgisson H; Nielsen HJ; Christensen IJ; Glimelius B; Brünner N Eur J Cancer; 2010 Dec; 46(18):3323-31. PubMed ID: 20619633 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Sharma R; Chattopadhyay TK; Mathur M; Ralhan R Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785 [TBL] [Abstract][Full Text] [Related]
16. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Clark LT; Pinsky DJ; Marmur JD Am Heart J; 2006 May; 151(5):1101.e1-8. PubMed ID: 16644343 [TBL] [Abstract][Full Text] [Related]
17. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159 [TBL] [Abstract][Full Text] [Related]
18. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221 [TBL] [Abstract][Full Text] [Related]
19. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. Tang L; Liu K; Wang J; Wang C; Zhao P; Liu J J Surg Oncol; 2010 Oct; 102(5):428-32. PubMed ID: 20672316 [TBL] [Abstract][Full Text] [Related]
20. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Talvensaari-Mattila A; Turpeenniemi-Hujanen T Breast Cancer Res Treat; 2005 Jan; 89(1):29-34. PubMed ID: 15666194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]